Cardiac Progenitor Cells

Overview

UCT-WJ-MSC–derived cardiac progenitors capable of differentiating into cardiomyocytes, endothelial cells, and smooth muscle cells; designed for myocardial regeneration after infarction or heart failure

Related: Stem Cells Overview • Cardiac Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Clinical Overview

Cardiac Progenitor Cells (CPCs) derived from UCT-WJ-MSCs provide a non-invasive, immune-compatible approach to myocardial regeneration, building on a broader literature establishing MSCs as a viable cardiac regenerative therapy platform.^[1] The adult heart has negligible regenerative capacity; following myocardial infarction (MI), irreversible cardiomyocyte death causes permanent scar formation and progressive heart failure. Akira CPCs address this through triple-lineage differentiation (cardiomyocytes, endothelial cells, smooth muscle cells) and a potent paracrine secretome. Delivered intracoronarily, intramyocardially, or intravenously, CPCs home to ischemic myocardium via SDF-1 gradients and exert both structural repair and functional improvement. Preclinical data show improved ejection fraction, reduced infarct size, and increased neovascularization. A multicenter RCT of WJ-MSC intracoronary infusion (n=116) demonstrated a clinically significant 7.8% absolute LVEF improvement at 18 months — establishing the clinical foundation for this product class.^[2]

Mechanism of Action

Cardiomyocyte Differentiation: NKX2.5+ / cTnI+ differentiated cells can form sarcomeric structures, exhibit spontaneous calcium transients, and couple electrically with host cardiomyocytes via connexin-43 gap junctions — restoring mechanical synchrony in infarcted zones.^[3]

Angiogenesis & Neovascularization: VEGF, Ang-1, FGF-2 secreted by CPCs stimulate endothelial proliferation and capillary formation in ischemic myocardium. CD31+ endothelial derivatives directly incorporate into new microvascular networks.

Anti-Apoptotic Paracrine Effects: IGF-1, HGF, and Bcl-2 upregulation in border-zone cardiomyocytes reduces ischemia-induced apoptosis. MSC-sourced miR-21 in CPC exosomes directly targets PTEN, activating PI3K/Akt survival signaling — a specific cardioprotective mechanism confirmed for exosomal miR-21a-5p.^[4]

Anti-Fibrotic Action: TGF-β pathway modulation, MMP secretion, and anti-fibrotic miRNAs (miR-146a, miR-let7) in CPC exosomes reduce scar expansion and prevent adverse ventricular remodeling.

Immunomodulation: Inherited MSC immune privilege suppresses excessive post-MI inflammation (which extends infarct size) via prostaglandin E2, IL-10, and IDO — without compromising essential inflammatory healing phases. Extracellular vesicles from cardiovascular progenitors have been shown to directly trigger a reparative immune response in infarcted hearts.^[5]

Electrical Remodeling Prevention: Post-infarction arrhythmia risk is primarily driven by electrical heterogeneity at the border zone, where poorly coupled, partially injured cardiomyocytes create substrates for re-entry circuits. Cx43-expressing CPCs restore gap junction coupling at the border zone, reducing this heterogeneity. In preclinical MI models, engraftment of Cx43-expressing cardiomyocytes reduced inducible ventricular tachycardia substrate and improved electrophysiologic homogeneity in the periinfarct territory, with no comparable protective effect from unmodified bone-marrow- derived cells in the same study.^[6]

Mitochondrial Donation to Hibernating Myocardium: Direct mitochondrial transfer from transplanted cells to ischemic cardiomyocytes via tunneling nanotubes and extracellular-vesicle-packaged mitochondria has been demonstrated to rescue mitochondrial function in acute ischemia/reperfusion injury models,^[7] including bone-marrow-derived MSCs rescuing injured cardiomyocyte-like H9c2 cells by transferring intact mitochondria through tunneling nanotubes in a simulated ischemia/reperfusion model,^[8] and iPSC-MSCs with high intrinsic MIRO1 expression achieving efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy.^[9] Hibernating myocardium — viable-but-contractile-dysfunctional tissue with a chronic energy/perfusion deficit^[10] — is a distinct, well-established clinical entity; applying mitochondrial-donation therapy there is a plausible extension of the acute-injury mechanism rather than a directly tested finding. UCT-derived cardiac progenitors, with high-quality young mitochondria, are proposed to offer this benefit in addition to their structural and paracrine mechanisms.

Key Biomarkers & Molecular Cargo

Potential Applications

• Acute Myocardial Infarction (AMI): intracoronary infusion at day 3–7 post-PCI for maximal paracrine benefit in the acute remodeling window — LVEF improvement, infarct size reduction.
• Chronic Ischemic Cardiomyopathy: IV or endomyocardial injection — recovery of hibernating myocardium, scar border-zone revascularization, anti-remodeling.
• Non-Ischemic Dilated Cardiomyopathy (DCM): IV or transendocardial — myocardial support, suppression of ongoing cardiomyocyte loss, VEGF-mediated microvascular restoration.
• Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF improvement demonstrated in a 201-patient HUC-MSC meta-analysis (3 RCTs); BNP and 6MWT effects not corroborated by that source.
• Diabetic Cardiomyopathy: anti-fibrotic, mitochondrial restoration, reduction of AGE-mediated cardiomyocyte damage.
• Myocarditis (post-viral / autoimmune): T-cell suppression, reduced macrophage infiltration, cardiomyocyte protection from immune-mediated destruction — allogeneic fetal-membrane-derived MSCs attenuated acute myocarditis in a rat model^[11] and suppressed Th1/Th17 T-cell responses in experimental autoimmune myocarditis.^[12]
• Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): fibrofatty replacement suppression; Cx43-mediated electrical remodeling support.
• Arrhythmias (post-ischemic): connexin restoration, electrical synchrony.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

The pivotal multicenter RCT (n=116 AMI patients) of intracoronary WJ-MSC infusion demonstrated LVEF improvement of 7.8 ± 0.9% vs 2.8 ± 1.2% in placebo at 18 months (P=0.001), with significant reductions in LV end-systolic and end-diastolic volumes and no immune reactions or arrhythmias throughout follow-up.^[2]

A meta-analysis of HUC-MSC therapy in heart failure and AMI (3 RCTs, 201 patients) found significant LVEF improvement (+3.21% mean difference) at 12-month follow-up versus placebo, though it did not find a statistically significant reduction in readmission or mortality risk.^[13]

A Phase III RCT (NCT05043610) is investigating WJ-MSC intracoronary delivery in anterior STEMI patients to prevent heart failure — a pivotal trial still in progress, establishing the regulatory pathway for a cardiac progenitor cell therapy indication rather than yet providing a completed readout.^[14]

Preclinical infarction models of cardiac-progenitor-cell transplantation report improved ejection fraction, reduced infarct scar size, increased capillary density in the infarct border zone, and reduced inducible arrhythmia substrate versus control — consistent with the mechanisms above, though this specific preclinical evidence base is not yet tied to a single verifiable published source and should be treated as directionally supportive rather than quantitatively definitive.